Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 19119114)

1.

Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy.

Lozzi GP, Coletti G, Peris K.

J Am Acad Dermatol. 2008 Nov;59(5 Suppl):S110-2. doi: 10.1016/j.jaad.2008.04.029. No abstract available.

PMID:
19119114
2.

Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.

Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G.

Arch Dermatol. 2000 Mar;136(3):374-8.

PMID:
10724200
3.

Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.

Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA.

Eur J Haematol. 2006 Oct;77(4):300-3. Epub 2006 Jul 19.

PMID:
16856917
4.
5.

Treatment of primary cutaneous B-cell lymphoma with rituximab.

Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L.

J Am Acad Dermatol. 2005 May;52(5):847-53.

PMID:
15858476
6.

Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.

Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L.

Br J Dermatol. 2005 Mar;152(3):541-4.

PMID:
15787825
7.

Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.

Clarke LE, Bayerl MG, Ehmann WC, Helm KF.

J Cutan Pathol. 2003 Aug;30(7):459-62.

PMID:
12859745
8.

Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.

Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K.

Clin Exp Dermatol. 2005 Jan;30(1):46-8.

PMID:
15663503
9.

The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.

Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.

J Cutan Pathol. 2005 Oct;32(9):616-21.

PMID:
16176299
10.

Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.

Park MY, Jung HJ, Park JE, Kim YC.

Eur J Dermatol. 2010 Jul-Aug;20(4):533-4. doi: 10.1684/ejd.2010.0987. Epub 2010 Jun 14. No abstract available.

PMID:
20542839
11.

[Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].

Gamo R, Calzado L, Pinedo F, López-Estebaranz JL.

Actas Dermosifiliogr. 2008 May;99(4):291-6. Review. Spanish.

PMID:
18394405
12.

Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.

Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J.

Leuk Lymphoma. 2007 Aug;48(8):1630-2. No abstract available.

PMID:
17701596
13.

[Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].

Abasq C, Duval-Modeste AB, Courville P, Joly P.

Ann Dermatol Venereol. 2008 Jun-Jul;135(6-7):509-11. doi: 10.1016/j.annder.2008.02.018. Epub 2008 May 27. French. No abstract available.

PMID:
18598807
14.

Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.

Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH.

J Am Acad Dermatol. 2008 Dec;59(6):953-7. doi: 10.1016/j.jaad.2008.08.005. Epub 2008 Sep 24.

PMID:
18817999
15.
16.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T.

Blood. 2009 May 14;113(20):4885-93. doi: 10.1182/blood-2008-08-175208. Epub 2009 Feb 26.

17.

Recurrent localized primary cutaneous marginal-zone B cell lymphoma.

Marmon S, Chu J, Patel R, Meehan S, Pomeranz MK.

Dermatol Online J. 2011 Oct 15;17(10):27. Review.

18.

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, Connors JM, Chhanabhai M, Brooks-Wilson A, Gascoyne RD.

Haematologica. 2009 Mar;94(3):423-7. doi: 10.3324/haematol.2008.001024. Epub 2009 Feb 11.

19.

Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase.

Paydas S, Yavuz S, Disel U, Sahin B, Ergin M.

Leuk Lymphoma. 2003 Dec;44(12):2165-6. No abstract available.

PMID:
14959867
20.

PUVA for cutaneous T-cell lymphoma. 10 years after.

Tanew A, Ortel B, Wolff K, Hönigsmann H.

Curr Probl Dermatol. 1986;15:232-7. No abstract available.

PMID:
3485032
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk